Getting personal with neoantigen-based therapeutic cancer vaccines

Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derive...

Full description

Saved in:
Bibliographic Details
Published in:Cancer immunology research 2013-07, Vol.1 (1), p.11-15
Main Authors: Hacohen, Nir, Fritsch, Edward F, Carter, Todd A, Lander, Eric S, Wu, Catherine J
Format: Article
Language:English
Subjects:
Antigens, Neoplasm - immunology
Cancer Vaccines - administration & dosage
Cancer Vaccines - immunology
Humans
Neoplasms - immunology
Neoplasms - therapy
Precision Medicine - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These "neoantigens" should provide highly specific targets for antitumor immunity. Although many challenges remain in producing and testing neoantigen-based vaccines customized for each patient, a neoantigen vaccine offers a promising new approach to induce highly focused antitumor T cells aimed at eradicating cancer cells.
ISSN:2326-6066
2326-6074
DOI:10.1158/2326-6066.CIR-13-0022